Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Paradigm Biopharmaceuticals Ltd. ( (AU:PAR) ) has issued an update.
Paradigm Biopharmaceuticals Ltd announced the release of 125,000 restricted securities from its Employee Share Plan, scheduled for 25 January 2025. This release is under the company’s Loan Funding agreement, with the loan due on specific conditions including employment termination or participant’s death, potentially impacting employee retention and financial obligations.
More about Paradigm Biopharmaceuticals Ltd.
Paradigm Biopharmaceuticals Ltd is a company in the biopharmaceutical industry, focusing on developing therapeutic treatments. They are known for their Employee Share Plan (ESP) and operate with a Loan Funding agreement to facilitate employee shares.
YTD Price Performance: 2.59%
Average Trading Volume: 8,470
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $104.8M
See more data about PAR stock on TipRanks’ Stock Analysis page.
